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Abstract
Background: Bipolar and other psychiatric disorders are associated with considerably increased risk of suicidal
behaviour, which may include self-poisoning with medication used to treat the disorder. Therefore, choice of
medication for treatment should include consideration of toxicity, especially for patients at risk. The aim of this
study was to estimate the relative toxicity of specific drugs within two drug categories, antipsychotics and mood
stabilizers, using large-scale databases to provide evidence that could assist clinicians in making decisions about
prescribing, especially for patients at risk of suicidal behaviour.
Method: Two indices were used to assess relative toxicity of mood stabilisers and antipsychotics: case fatality (the ratio
between rates of fatal and non-fatal self-poisoning) and fatal toxicity (the ratio between rates of fatal self-poisoning and
prescription). Mood stabilisers assessed included lithium [reference], sodium valproate, carbamazepine, and lamotrigine,
while antipsychotics included chlorpromazine [reference], clozapine, olanzapine, quetiapine and risperidone. Fatal self-
poisoning (suicide) data were provided by the Office for National Statistics (ONS), non-fatal self-poisoning data by the
Multicentre Study of Self-harm in England, and information on prescriptions by the Clinical Practice Research Datalink.
The primary analysis focussed on deaths due to a single drug. Cases where the drug of interest was listed as the likely
primary toxic agent in multiple drug overdoses were also analysed. The study period was 2005–2012.
Results: There appeared to be little difference in toxicity between the mood stabilisers, except that based on case
fatality where multiple drug poisonings were considered, carbamazepine was over twice as likely to result in death
relative to lithium (OR 2.37 95% CI 1.16–4.85). Of the antipsychotics, clozapine was approximately18 times more likely
to result in death when taken in overdose than chlorpromazine (single drug case fatality: OR 18.53 95% CI 8.69–39.52).
Otherwise, only risperidone differed from chlorpromazine, being less toxic (OR 0.06 95% CI 0.01–0.47).
Conclusions: There was little difference in toxicity of the individual mood stabilisers. Clozapine was far more toxic than
the other antipsychotics. The findings are relevant to prescribing policy, especially for patients at particular risk of
suicidal behaviour.
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Background
Mood stabilisers and antipsychotics are used to treat psychi-
atric disorders such as bipolar disorder and schizophrenia. It
is estimated that 5–8% of people with bipolar disorder die
by suicide [1]. However, other studies suggest a higher rate
[2, 3]. The equivalent figure for schizophrenia is 5% [4]. The
method of suicide used by people with these disorders is
often self-poisoning [5]. One important consideration when
prescribing drugs for these conditions is their relative
toxicity in overdose, because if patients self-poison they
are likely to use their prescribed medication [6, 7]. Several
mood stabilisers are also anticonvulsants used to manage
epilepsy. Epilepsy is also associated with an increased risk
of suicidal behaviour, including self-poisoning [8]. It is
therefore important for clinicians be as well-informed as
possible about the relative toxicity of drugs they prescribe
for a given condition [9]. Previous work on the use of
psychotropic medication in non-fatal self-poisoning in
patients in Ireland suggested that more than 10% of the
sample ingested antipsychotics, while approximately 7%
used mood stabilisers [7]. Most of these drugs had been
prescribed to the patient prior to the overdose. Establishing
the relative toxicity of mood stabilisers and antipsychotics
is important for clinical practice and regulatory agencies.
The main aim of this study was to estimate the relative
toxicity of specific drugs within two drug categories,
antipsychotics and mood stabilisers, using large-scale
databases. This will provide evidence that could assist
clinicians in making decisions about prescribing, especially
for patients at risk of suicidal behaviour.
Methods
We investigated the relative toxicity of the mood stabilisers
and antipsychotics most often used for fatal and/or non-
fatal self-poisoning in the UK. We considered antipsy-
chotics and mood stabilisers together because both are
used as treatments for severe mental illnesses. We used
two approaches: first, case fatality, in which the number
of self-poisoning deaths involving a specific drug is com-
pared to the number of episodes of non-fatal
self-poisoning involving this drug [10, 11]; second, fatal
toxicity, in which the number of deaths by self-poisoning
involving a specific drug is compared to the number of in-
dividuals prescribed this drug [12]. We previously used
these approaches to investigate the relative toxicity of
antidepressants, [11] to highlight the toxicity of
co-proxamol, [13] and to examine the relatively toxicity of
benzodiazepines [14].
Study drugs
The mood stabilisers investigated in this study were
lithium and the anti-convulsants sodium valproate,
carbamazepine and lamotrigine. The antipsychotics
investigated included chlorpromazine, clozapine, olanzapine,
quetiapine and risperidone. The period covered by the study
was 2005–2012.
Deaths
We obtained information on drug poisoning deaths
receiving a verdict of intentional self-poisoning (ICD-10
codes X60–64) or death of undetermined intent (open
verdict; ICD-10 codes Y10-Y14), that involved either
mood stabilisers or antipsychotics, from the Office of Na-
tional Statistics based on deaths in individuals aged 15
years and over occurring during 2005–2012 in England
registered to the end of 2014. We included open verdicts
as this is policy with regard to suicide statistics and re-
search in the UK because a high proportion are thought
to be probable suicides [15–17]. Intentional
self-poisonings and open verdicts are henceforth termed
‘suicides’. We conducted two analyses. The first included
only deaths involving single drugs (in the presence or ab-
sence of alcohol), while the second included these deaths
together with deaths where the drug under investigation
was the first drug recorded by the coroner in multiple
drug overdoses, again with or without alcohol. This as-
sumes that the first drug recorded was likely to have
been the primary agent involved in the death. Death
data were obtained for males and females separately for
all drugs.
Non-fatal self-poisoning
Data on non-fatal self-poisoning was obtained from the
Multicentre Study of Self-harm in England [18]. The Mul-
ticentre Study of Self-harm collects data on all presenta-
tions for self-harm to the emergency departments at five
general hospitals. These include one hospital in Oxford,
three hospitals in Manchester and two hospitals in
Derby that merged into one in 2009. Self-harm is defined
as intentional self-poisoning or self-injury, irrespective of
the motivation or degree of suicidal intent, [19] and
self-poisoning includes the intentional ingestion of more
than the prescribed amount of any drug. This applies
whether or not there is evidence that the act was intended
to result in death. Data were collected on gender, age, date
and method of self-poisoning, including the specific drugs
ingested. Episodes of non-fatal self-poisoning include all
non-fatal overdoses involving the mood stabilisers and
antipsychotics under investigation, regardless of
whether or not other drugs or alcohol were involved.
We extracted data for all episodes of non-fatal self-
poisoning involving individuals aged 15 years and over
which included the mood stabiliser or antipsychotic under
investigation. The analysis included only episodes of self-
harm by individuals who resided in the catchment area of
Oxford City, The City of Manchester and Derby Unitary
Area at the time of the episode, because reliable mid-year
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population estimates were available for these areas. Mid-
year population estimates were required to calculate rates.
Prescriptions
We obtained data on prescriptions of the study drugs
for individuals aged 15 years and over from the Clinical
Practice Research Datalink (CPRD [20]), which is a gov-
ernmental research service which provides anonymised
primary care records that can be used for public health
research. It currently includes data on just under 10% of
the UK population. Patients included in the CPRD have
been found to broadly represent the UK population in
terms of age, sex and ethnicity [21]. Information from
the CPRD included the number of patients registered
with the general practices appearing in the CPRD database
and the number of individuals who were prescribed the
specific study medication, by individual year (2005–2012),
age and gender.
Statistical analysis
We calculated rates of non-fatal self-poisoning based on
the number of episodes of non-fatal self-poisoning per
100,000 person-years using mid-year population estimates
obtained from ONS for Oxford City, the City of Manchester,
and Derby Unitary area for 2005–2012. We calculated rates
of suicide by self-poisoning per 100,000 person-years using
England’s mid-year population estimates for 2005–2012,
which we obtained from the Office for National Statistics
(ONS). Prescription rates were calculated as the number of
individuals prescribed a specific medication per 100,000
person-years registered with the general practices in
the CPRD during 2005–2012. All analyses were carried
out using the Poisson distribution with exact 95% CIs.
Our measures of relative toxicity included case fatality
and fatal toxicity. Case fatality was calculated by taking the
number of deaths by self-poisoning in England during
2005–2012 attributed to a given study drug divided by the
number of episodes of non-fatal self-poisoning involving
this drug during the equivalent period from the Multicentre
Study of Self-harm in England and standardising these
ratios to the risk for lithium (for the mood stabilisers) and
chlorpromazine (for the antipsychotics). Fatal toxicity was
calculated using the number of deaths by self-poisoning in
England during 2005–2012 attributed to a drug divided by
the number of individuals prescribed this drug during the
equivalent period and standardised to the risk for lithium
(for the mood stabilisers) and chlorpromazine (for the anti-
psychotics). We were not able to calculate a fatal toxicity
measure for clozapine because this drug is rarely prescribed
via GP surgeries. For this drug we therefore relied on case
fatality. Lithium and chlorpromazine were selected as
reference drugs on the basis of long-term use (these are
older drugs with a substantial history of use). Confidence
intervals for relative toxicity were calculated using the
Poisson distribution.
We conducted two sets of analyses for each of the toxicity
indices (fatal toxicity and case fatality). First, we included
only deaths involving single drugs (with or without alcohol).
Second, we also included cases of deaths involving multiple
drugs where the drug of interest was the first drug recorded
by the coroner, on the basis that this drug was likely to have
been the main cause of death.
We also calculated the proportion of individuals for
whom alcohol was mentioned in the coroner’s report for
each of the drugs investigated. Statistical analyses were
carried out using Excel 2013 and Stata 14.1.
Ethical approval
The monitoring systems for self-harm in Oxford and
Derby have approval from local Health /Psychiatric Research
Ethics Committees to collect data on self-harm for local and
multicentre projects. Self-harm monitoring in Manchester is
part of a clinical audit system, and has been ratified by the
local Research Ethics Committee. All three monitoring
systems are fully compliant with the Data Protection Act of
1998. All centres have approval under Section 251 of the
National Health Services (NHS) Act 2006 (formerly Section
60, Health and Social Care Act 2001) to collect patient
identifiable information without patient consent.
We also obtained specific Independent Scientific Advisory
Committee (ISAC) approval from the CPRD (protocol
number 14_064R2) and also from ONS to obtain mortality
data.
Results
Mood Stabilisers
During the eight-year study period (2005–2012) there
were 59 suicide deaths in England due to single-drug
poisoning with mood stabilisers and a further 37 cases
where more than one drug was listed as contributing to
the death but the mood stabiliser under investigation was
listed first (Table 1). Of these 96 deaths, 55% involved
males and 45% females. These were from a total of 3083
poisoning suicide deaths occurring during the study
period. Of the 59 deaths, 7% were in people age 15–24,
61% were in people age 25–54, and 32% in people age 55
or older. In 51 cases there was a verdict of intentional
self-poisoning and in 45 cases a verdict of undetermined
intent.
During the same period, 687 non-fatal self-poisonings
with mood stabilisers were identified through the Multi-
centre Study of Self-harm in England. Data taken from
the CPRD (which contains records from approximately
10% of the GP surgeries in England) indicated that there
were on average 46,860 prescriptions per year of the mood
stabilisers under investigation during the 2005–2012
period (Table 1).
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Case fatality indices
Using single-drug deaths, carbamazepine appeared to be
over twice as likely to result in death when taken in
overdose compared to lithium, although the evidence
was weak. There was no indication of major differences
in toxicity for the other mood stabilizers (Table 2).
The results were similar when we also included cases in
which multiple drugs had been consumed in self-poisoning
deaths but the drug of interest was listed first, except that
the result for carbamazepine was statistically significant.
This indicates that overdoses with carbamazepine were
more likely to result in death than overdoses with lithium
(Table 2).
Fatal toxicity indices
Measures of fatal toxicity showed a similar pattern of
results to those for case fatality, except that the finding
for carbamazepine was attenuated and consistent with
chance (Table 3). Using additional cases in which the
drug of interest was listed first where multiple drugs
had been ingested indicated the same pattern.
Antipsychotics During the study period there were 143
suicide deaths due to single-drug poisoning with major
tranquillisers and a further 61 in which there was evidence
of multiple-drug ingestion but the drug of interest was
listed first. Of these 204 deaths, 66% involved males and
34% females. These were from a total of 3083 suicides
involving self-poisoning. In terms of age breakdown,
6% of deaths occurred in people aged 15–24 years, 80%
in people aged 25–54 year and 14% of deaths in people
55 years or older. In 91 cases there was a verdict of
intentional self-poisoning and in 113 cases an open
verdict.
There were 1631 non-fatal self-poisoning episodes in
the Multicentre Study of Self-harm in England in which
antipsychotics were ingested. During the equivalent period,
32,758 individuals in the CPRD were prescribed the study
antipsychotics yearly.
Case fatality indices
The toxicity of risperidone was lower than the reference
drug chlorpromazine. Clozapine appeared to be almost
19 times more toxic in overdose than chlorpromazine.
Including deaths where the drug of interest was listed
first in multiple drug deaths produced a similar pattern
of results (Table 2).
Fatal toxicity indices
The fatal toxicity approach using single-drug data also
showed risperidone to have lower toxicity relative to
chlorpromazine. Using cases where the drug of interest
was listed first in multiple drug deaths produced the
same pattern of results (Table 3). As noted earlier, the
fatal toxicity approach could not be used for clozapine
since complete data on prescribing were not available
from the CPRD because most prescriptions are provided
by hospitals.
Alcohol
Alcohol was involved in very few of the deaths. Alcohol
was mentioned in the coroner’s report in only five cases
(8.5%) of single-drug deaths involving mood stabilisers,
and in 22 deaths involving antipsychotics (15.4%). In neither
drug group was there any indication of excess alcohol
involvement with specific drugs.
Discussion
We have examined the relative toxicity of individual
mood stabilisers and antipsychotics using two measures
Table 3 Fatal toxicity indices – number of suicides involving a
given drug per individuals prescribed this drug relative to a.
lithium or b. chlorpromazine
Odds ratio (95% CI)
Single drug only Single plus first listed drug
A. Mood Stabilisers
Lithium 1.0 1.0
Sodium Valproate 0.80 (0.31–2.07) 0.58 (0.27–1.25)
Carbamazepine 1.45 (0.61–3.45) 1.47 (0.75–2.89)
Lamotrigine 0.54 (0.17–1.77) 0.78 (0.34–1.80)
B. Antipsychotics
Chlorpromazine 1.0 1.0
Risperidone 0.04 (0.01–0.29) 0.05 (0.01–0.21)
Quetiapine 1.26 (0.66–2.40) 1.29 (0.77–2.15)
Olanzapine 1.63 (0.87–3.05) 1.46 (0.89–2.41)
Table 2 Case fatality indices– number of suicides involving a
given drug per non-fatal self-poisoning episode relative to a.
lithium and b. chlorpromazine
Odds ratio (95% CI)
Single drug only Single and first listed drug
A. Mood Stabilisers
Lithium 1.0 1.0
Sodium Valproate 0.92 (0.35–2.45) 0.66 (0.30–1.49)
Carbamazepine 2.33 (0.94–5.74) 2.37 (1.16–4.85)
Lamotrigine 0.68 (0.20–2.28) 0.97 (0.40–2.35)
B. Antipsychotics
Chlorpromazine 1.0 1.0
Risperidone 0.06 (0.01–0.47) 0.08 (0.02–0.34)
Quetiapine 1.12 (0.58–2.18) 1.15 (0.67–1.97)
Olanzapine 1.84 (0.97–3.52) 1.65 (0.97–2.80)
Clozapine 18.53 (8.69–39.52) 13.38 (6.88–26.00)
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of toxicity – case fatality and fatal toxicity. Both the case
fatality and fatal toxicity approaches produced similar
results. The more conservative method of including only
deaths where one drug was listed on the coroner’s report
was confirmed by a secondary analysis in which we also
included cases with the involvement of more than one
drug, but where the drug of interest was listed first. This
second approach was used on the basis that the first
drug was likely to have been the main cause of death. This
supports the findings, as does the convergence of the re-
sults of both the fatal toxicity (not possible for clozapine)
and case fatality methods.
Mood Stabilisers
Perhaps the most notable finding regarding the mood
stabilisers was that lithium, contrary to a tendency to
regard this drug as particularly toxic in overdose [22]
did not appear to be more toxic compared to the other
mood stabilisers included in this study. This finding,
together with increasing evidence that lithium may have
specific anti-suicidal effects, should encourage clinicians
to consider the use of lithium in patients with recurrent
affective disorder, including those at risk of suicide.
There was some indication to suggest that carbamazepine
may be more toxic relative to the other mood stabilisers,
although evidence in support of this was shown in only one
of the four models assessing the relative toxicity of carba-
mazepine. Carbamazepine, like most of the other mood
stabilisers, is an anticonvulsant. While people with bipolar
disorder have an elevated risk of taking prescribed drugs in
overdose, [23] it is also important to recognise that risks of
both suicide and non-fatal self-poisoning are elevated in
people with epilepsy [8, 24]. Although antiepileptic drugs in
general may not lead to higher rates of suicidal behaviour,
carbamazepine has been found to be associated with
increased levels of suicide attempts compared to other
anti-epileptics [25] and carbamazepine is related to a
higher risk of suicide attempts in bipolar disorder [26].
Carbamazepine also interacts with other drugs, which
may increase its toxicity [27].
Neither of the other drugs (sodium valproate or lamo-
trigine) showed any sign of elevated toxicity relative to
the reference drug.
Antipsychotics
In this analysis, clozapine was the most toxic of the
drugs examined, although only the case fatality approach
could be used to assess its relative toxicity because clo-
zapine is prescribed mainly from hospitals. Clozapine is
an atypical antipsychotic usually used to treat patients
with schizophrenia who have not responded to other
antipsychotics [28]. Its use is already tightly regulated in
the UK, [29] mainly because of the risk of blood dyscrasia
[30]. Clozapine is often used to treat serious psychotic
disorders of patients who have not responded to treatment
with other drugs; patients who may already be at higher
risk of suicide. However, in one major trial clozapine was
found to reduce suicidal behaviour in people with schizo-
phrenia who were at high risk of suicide, [31] a result
which has support from longitudinal analysis of patient
records on and off clozapine. [32] This provides support
for the suggestion that suicide prevention could be an
additional indication for clozapine. It is approved for this
indication in the USA. [33] Nevertheless, the high toxicity
of the drug in overdose needs to be considered in manage-
ment. There should be careful monitoring for possible
suicidal ideation and possibly controlled availability of the
drug and regular monitoring of mood and suicidal idea-
tion where risk is thought to be elevated.
Risperidone was also found to have lower toxicity than
the reference drug chlorpromazine using both case fatality
and fatal toxicity approaches, while both olanzapine and
quetiapine were not found to be more toxic than the refer-
ence drug. These findings should be taken into account
when prescribing antipsychotics.
Strengths and limitations
In this study we used two methods to evaluate the rela-
tive toxicity of mood stabilizers and antipsychotics (case
fatality and fatal toxicity), the results of which largely
converged. Findings from the primary analysis using
only deaths attributed to a single drug were consistent
with findings using multiple-drug deaths, where the drug
of interest was listed first in the coroner’s report. These
analyses were based on several large datasets, including
all the deaths in England attributed to self-poisoning
between 2005 and 2012. Another strength is the consistent
findings between the results of the fatal toxicity and case
fatality approaches, although only the latter approach was
possible for clozapine.
There are also several limitations to this work. Perhaps
most importantly, our data were taken from different
sources. The mortality data were obtained from ONS and
covered the entire population of England, prescription data
were provided by the CPRD and comprised medical records
for just under 10% of the UK population, and data on
non-fatal self-poisoning were obtained from the Multicen-
tre Study of Self-harm in England, which covers three cities
in England. However, these last two sources provided
relatively large datasets and are likely to be reasonably
representative of the population as a whole [21].
We also have limited data on the cause of death. There
is no information on dosage of drugs taken in overdose or
relative blood levels of drugs (in the cases where multiple
drugs were taken). Therefore we cannot draw firm conclu-
sions on drug interactions. However, this was mitigated by
using single-drug deaths in our primary analyses. Simi-
larly, we only have information on the reported presence
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or absence of alcohol in the bloodstream but no informa-
tion on alcohol levels and hence the contribution of alcohol
to deaths. We included deaths of undetermined intent
(open verdicts) in line with current UK policy on suicide
research. This is because the majority of deaths with
this verdict are probable suicides, [16, 15] although it is
not possible to be certain about intent in such cases.
Data on non-fatal self-poisoning was taken from data
collected from emergency departments. It is important
to note that self-harm in the community frequently does
not result in presentation to an emergency department,
although information from studies of young people indi-
cate that hospital presentation is more likely where the
method of self-harm is self-poisoning [34, 35]. It should
nonetheless be acknowledged that the number of non-
fatal poisonings will be an underestimate. Of course, this
problem does not affect the relative toxicity findings.
It is possible that differences in patient groups may
have contributed to the observed findings. For example,
patients treated with lithium are likely to have bipolar
disorder, while those treated with anticonvulsants may
have a range of disorders including bipolar, epileptic or
borderline personality disorders. The patients in each
group may therefore differ in their risk of suicide or
self-harm and access to potentially lethal doses of medica-
tions. As well, certain drugs prescribed for a given disorder
may be a more effective treatment but also more toxic in
overdose, meaning that it may be difficult to interpret the
risks and benefits using this approach.
Conclusions
The finding that lithium did not appear to have elevated
toxicity when used for self-poisoning and that very few
deaths occurred due to lithium ingestion in overdose
may suggest the potential value of lithium as an anti-sui-
cidal agent in people with mood disorders. The possible
excess toxicity of carbamazepine in overdose compared to
the other mood stabilisers should be borne in mind when
prescribing, especially in patients with bipolar disorder or
epilepsy thought to be at risk of suicidal behaviour.
Among the antipsychotics, clozapine is clearly far
more toxic than other drugs. This adds to the need for
very careful management when treating patients who are
prescribed this drug, especially if they are considered to
be at risk of suicidal behaviour. Risperidone was found
to have lower toxicity than the reference drug
chlorpromazine.
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